Jeger Raban V, Pfister Otmar, Radovanovic Dragana, Eberli Franz R, Rickli Hans, Urban Philip, Pedrazzini Giovanni, Stauffer Jean-Christophe, Nossen Jörg, Erne Paul
Department of Cardiology, University Hospital Basel, Basel, Switzerland.
AMIS Plus Data Centre, Epidemiology, Biostatistics, and Prevention Institute, University of Zurich, Zurich, Switzerland.
Clin Cardiol. 2017 Oct;40(10):907-913. doi: 10.1002/clc.22745. Epub 2017 Jun 9.
Data on temporal trends of heart failure (HF) in acute coronary syndrome (ACS) are scarce.
Improved treatment options may have led to lower case-fatality rates (CFRs) during the last years in ACS complicated by HF.
Patients of the nationwide Acute Myocardial Infarction in Switzerland (AMIS)-Plus ACS registry were analyzed from 2000 to 2014.
Of 36 366 ACS patients, 3376 (9.3%) had acute or chronic HF, 2111 (5.8%) de novo acute HF (AHF), 964 (2.7%) chronic HF (CHF), and 301 (0.8%) acute decompensated CHF (ADCHF). In-hospital CFRs were highest in patients with ADCHF (32.6%) and de novo AHF (29.7%), followed by patients with CHF (12.9%) and without HF (3.2%, P < 0.001). Although in-hospital CFRs gradually decreased in CHF patients (14.3% to 4.5%, P = 0.003) and patients without HF (3.5% to 2.2%, P < 0.001), they remained high in patients with ADCHF (36.4% to 40.0%, P = 0.45) and de novo AHF (50.0% to 29.4%, P = 0.37). Although there was an increase in specific ACS therapies in the cohort over time, ACS patients with HF received significantly less pharmacological and interventional ACS therapies than patients without HF. There was no significant change in HF medication rates except less frequent use of β-blockers and diuretics in de novo AHF patients in recent years.
HF is present in 1 out of 10 patients presenting with ACS and is associated with high in-hospital CFRs, particularly in acute HF. Although advances in ACS therapy improved in-hospital CFRs in patients with no HF or CHF, CFRs remained unchanged and high in patients with acute HF and ACS over the last decade.
关于急性冠状动脉综合征(ACS)中心力衰竭(HF)的时间趋势的数据匮乏。
在过去几年中,治疗方案的改善可能已使合并HF的ACS患者的病死率(CFR)降低。
对瑞士全国性急性心肌梗死(AMIS)-Plus ACS注册研究中的患者进行了2000年至2014年的分析。
在36366例ACS患者中,3376例(9.3%)患有急性或慢性HF,2111例(5.8%)为新发急性HF(AHF),964例(2.7%)为慢性HF(CHF),301例(0.8%)为急性失代偿性CHF(ADCHF)。ADCHF患者(32.6%)和新发AHF患者(29.7%)的院内CFR最高,其次是CHF患者(12.9%)和无HF患者(3.2%,P<0.001)。尽管CHF患者(从14.3%降至4.5%,P=0.003)和无HF患者(从3.5%降至2.2%,P<0.001)的院内CFR逐渐降低,但ADCHF患者(从36.4%至40.0%,P=0.45)和新发AHF患者(从50.0%至29.4%,P=0.37)的CFR仍居高不下。尽管随着时间推移队列中特定ACS治疗有所增加,但合并HF的ACS患者接受的药物和介入性ACS治疗明显少于无HF患者。除近年来新发AHF患者中β受体阻滞剂和利尿剂的使用频率降低外,HF药物使用率无显著变化。
每10例ACS患者中就有1例存在HF,且与高院内CFR相关,尤其是在急性HF中。尽管ACS治疗的进展改善了无HF或CHF患者的院内CFR,但在过去十年中,急性HF合并ACS患者的CFR保持不变且居高不下。